粪菌移植治疗帕金森病的系统评价、荟萃分析与荟萃回归
该系统评价与荟萃分析纳入8项研究共220例轻中度帕金森病患者,评估粪菌移植的疗效与安全性。结果显示粪菌移植与UPDRS第三部分运动功能(MD -9.67)和便秘严重度(Wexner评分MD -3.91)的改善相关,但部分获益在24周未能维持,胃肠道不良事件更常见。
要点
- 粪菌移植可能短期改善帕金森病运动症状和便秘。
- 仅纳入随机对照试验时,UPDRS第三部分改善仍显著。
- 胃肠道不良事件在粪菌移植组更常见但多为轻中度。
核心结论
- 粪菌移植可能为帕金森病提供短期的运动和胃肠道症状改善,但效应似乎短暂。
研究设计与样本
- 系统评价与荟萃分析,遵循PRISMA指南,方案注册于PROSPERO(CRD420251142846)。
- 检索MEDLINE、Embase和Cochrane Library自建库至2025年9月,纳入随机对照试验和观察性研究。
- 纳入8项研究(5项随机对照试验和3项观察性研究),共220例轻中度帕金森病成人患者。
主要发现
- 粪菌移植与UPDRS第三部分运动功能显著改善相关(MD -9.67,95% CI -16.81至-2.53)。
- 粪菌移植与便秘严重度显著改善相关(Wexner评分MD -3.91,95% CI -7.68至-0.13)。
- UPDRS第二部分和PDQ-39在12周有改善但24周未维持。
- 仅随机对照试验分析中,UPDRS第三部分改善仍显著(MD -6.82,95% CI -11.23至-2.40)。
- 荟萃回归显示较长随访与UPDRS第二部分更大改善相关(p = 0.043)。
关键数值与推荐
- 粪菌移植组胃肠道不良事件更频繁(风险比3.12,95% CI 1.14-8.53),主要为轻中度。
临床怎么用
- 粪菌移植可能作为帕金森病短期改善运动和便秘症状的辅助策略,但需关注胃肠道不良反应。
- 因证据来自小样本和异质性研究,临床应用应谨慎并优先考虑临床试验背景。
局限性
- 样本量小、研究间异质性大且随访时间有限,限制结论可靠性。
- 合并估计包含观察性研究证据,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Parkinson disease (PD) is a progressive neurodegenerative disorder increasingly linked to gut microbiota dysbiosis, which may influence disease mechanisms and symptom expression. Fecal microbiota transplantation (FMT) targets the gut-brain axis, but clinical evidence remains inconsistent. This study aimed to evaluate the efficacy and safety of FMT in PD. METHODS: We conducted a systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, with protocol registration in International Prospective Register of Systematic Reviews (CRD420251142846). MEDLINE, Embase, and the Cochrane Library were searched from inception through September 2025. Randomized controlled trials (RCTs) and observational studies enrolling adults with mild-to-moderate PD who received FMT through any administration route were eligible. The primary outcome was motor function assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) part III. Secondary outcomes included UPDRS part II, quality of life (Parkinson's Disease Questionnaire-39 [PDQ-39]), constipation severity (Wexner score), and adverse events. Random-effects models pooled effect estimates with 95% CIs, and exploratory meta-regression assessed follow-up duration, publication year, and sample size. RESULTS: Eight studies (5 RCTs and 3 observational studies) including 220 participants were analyzed. The mean age ranged from approximately 60 to 70 years, and women comprised about 40% of participants. FMT was associated with significant improvement in motor function (UPDRS part III: mean difference [MD] -9.67, 95% CI -16.81 to -2.53) and constipation severity (Wexner score: MD -3.91, 95% CI -7.68 to -0.13). Improvements in UPDRS part II and PDQ-39 were observed at 12 weeks but not sustained at 24 weeks. In RCT-only analyses, UPDRS part III improvement remained significant (MD -6.82, 95% CI -11.23 to -2.40), whereas other outcomes were not consistently significant. Meta-regression indicated that longer follow-up was associated with greater improvement in UPDRS part II (p = 0.043). FMT was generally well tolerated; however, gastrointestinal adverse events were more frequent in the FMT group (risk ratio 3.12, 95% CI 1.14-8.53), predominantly mild to moderate. DISCUSSION: FMT may provide short-term improvements in motor and gastrointestinal symptoms in PD, but effects appear transient. Small sample sizes, heterogeneity, and limited follow-up restrict conclusions, underscoring the need for larger randomized trials. Pooled estimates reflected evidence from observational studies and should be interpreted cautiously.
引用
- Pereira MAOM, Tudella GCN, Klostermann AU, et al. Fecal Microbiota Transplantation in Parkinson Disease: A Systematic Review, Meta-Analysis, and Meta-Regression. Neurology. 2026. PMID: 42302222. doi:10.1212/WNL.0000000000218175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。